James A Hoxie

Author PubWeight™ 68.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004 5.31
2 Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005 4.68
3 HIV vaccine research: the way forward. Science 2008 3.86
4 Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 2002 3.47
5 Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012 3.15
6 An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011 2.60
7 Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog 2010 2.55
8 Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol 2003 2.42
9 Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol 2002 2.23
10 High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 2011 2.14
11 Characterization of neutralizing antibodies to West Nile virus. Virology 2005 1.81
12 Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol 2005 1.76
13 Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5. Blood 2010 1.72
14 V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog 2007 1.55
15 Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 2011 1.50
16 Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol 2008 1.44
17 Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol 2012 1.44
18 A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein. Mol Biol Cell 2006 1.38
19 DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol 2006 1.31
20 Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain. J Virol 2009 1.26
21 Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology 2008 1.26
22 Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4. J Virol 2009 1.24
23 Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. J Virol 2011 1.18
24 Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors. J Virol 2007 1.09
25 Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. J Virol 2013 1.04
26 Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor. J Virol 2009 1.03
27 Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions. Retrovirology 2013 0.99
28 Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists. J Virol 2007 0.97
29 Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J Virol 2009 0.96
30 Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins. J Virol 2003 0.95
31 Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry. ACS Chem Biol 2011 0.94
32 Vaccine-delivered HIV envelope inhibits CD4(+) T-cell activation, a mechanism for poor HIV vaccine responses. Blood 2006 0.90
33 Loss of a tyrosine-dependent trafficking motif in the simian immunodeficiency virus envelope cytoplasmic tail spares mucosal CD4 cells but does not prevent disease progression. J Virol 2012 0.88
34 Simian immunodeficiency virus (SIV)/immunoglobulin G immune complexes in SIV-infected macaques block detection of CD16 but not cytolytic activity of natural killer cells. Clin Vaccine Immunol 2006 0.88
35 Mutations that destabilize the gp41 core are determinants for stabilizing the simian immunodeficiency virus-CPmac envelope glycoprotein complex. J Biol Chem 2002 0.87
36 CD4+ T cells support production of simian immunodeficiency virus Env antibodies that enforce CD4-dependent entry and shape tropism in vivo. J Virol 2013 0.83
37 Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist. J Virol 2010 0.82
38 Trophoblasts are productively infected by CD4-independent isolate of HIV type 1. AIDS Res Hum Retroviruses 2002 0.82
39 Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env. J Virol 2005 0.80
40 A single amino acid mutation in the envelope cytoplasmic tail restores the ability of an attenuated simian immunodeficiency virus mutant to deplete mucosal CD4+ T cells. J Virol 2013 0.76
41 Modification of a viral envelope glycoprotein cell-cell fusion assay by utilizing plasmid encoded bacteriophage RNA polymerase. J Virol Methods 2005 0.76
42 CCR5 mimicry by sulfated human anti-HIV-1 antibodies. Cell 2003 0.76
43 Translating social and behavioral science research to the AIDS epidemic: a center for AIDS research perspective. J Acquir Immune Defic Syndr 2013 0.75
44 A plea for justice for jailed medical workers. Science 2006 0.75